Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Product based on intracellular mycobacterium pure protein derivative and recombinant mycobacterium tuberculosis fusion protein, application and use method

A technology of protein derivatives and mycobacteria, applied in the field of biological proteins, can solve the problems of affecting the treatment of patients, different treatment plans, time-consuming, etc., and achieve reliable theoretical basis and reference basis, short identification time and high significance.

Inactive Publication Date: 2021-10-01
成都可恩生物科技有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Based on the fact that the clinical symptoms of NTM disease and tuberculosis are similar, but the treatment options of the two are completely different, and for conventional NTM disease diagnosis methods, it usually takes a long time (more than 30 days), which may seriously affect the treatment of patients. Therefore, there is an urgent need for a Simple and fast detection reagent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Product based on intracellular mycobacterium pure protein derivative and recombinant mycobacterium tuberculosis fusion protein, application and use method
  • Product based on intracellular mycobacterium pure protein derivative and recombinant mycobacterium tuberculosis fusion protein, application and use method
  • Product based on intracellular mycobacterium pure protein derivative and recombinant mycobacterium tuberculosis fusion protein, application and use method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] This example discusses the combination of pure protein derivatives of Mycobacterium intracellulare and recombinant Mycobacterium tuberculosis fusion protein to induce delayed hypersensitivity in guinea pigs sensitized to the attenuated strain of Mycobacterium tuberculosis (CMCC93020), so as to further improve the technical scheme illustrate.

[0041] S1: guinea pig

[0042] SPF grade guinea pigs with a body weight of 300-500g were raised in IVC cages (3 guinea pigs per cage, the litter was changed twice a week, free access to food and water).

[0043] S2: skin test

[0044] Tuberculin pure protein derivative skin test negative guinea pigs.

[0045] S3: Allergens

[0046] Take the sensitizer (50mg / mL) of the attenuated strain of Mycobacterium tuberculosis (CMCC93020), and sterilize it at 121°C for 20min.

[0047] S4: Sensitization

[0048] Inject 0.2mL of the allergenic bacteria solution (50mg / mL) in the groin, and perform the second sensitization 3 weeks after the ...

Embodiment 2

[0055] This example discusses the combination of pure protein derivatives of Mycobacterium intracellulare and recombinant Mycobacterium tuberculosis fusion protein against Mycobacterium intracellulare (CMCC 95002) and Guinea pigs sensitized with Mycobacterium avium (CMCC95001) induced delayed hypersensitivity to further illustrate the technical solution.

[0056] S1: guinea pig

[0057] SPF grade guinea pigs with a body weight of 300-500g were raised in IVC cages (3 guinea pigs per cage, the litter was changed twice a week, free access to food and water).

[0058] S2: skin test

[0059] Tuberculin pure protein derivative skin test negative guinea pigs.

[0060] S3: Allergens

[0061] Allergens (50 mg / mL) of Mycobacterium intracellulare (CMCC 95002) and Mycobacterium avium (CMCC95001) were taken and sterilized at 121°C for 20 minutes.

[0062] S4: Sensitization

[0063] Inject 0.2mL of the allergenic bacteria solution (50mg / mL) in the groin, and perform the second sensitiz...

Embodiment 3

[0072] This example discusses the combination of pure protein derivatives of Mycobacterium intracellulare and recombinant Mycobacterium tuberculosis fusion protein against Mycobacterium kansasii (CMCC 95013) and Hai Mycobacterium (CMCC 95014) and simian mycobacterium (CMCC95015) sensitized guinea pigs induced delayed hypersensitivity reactions to further illustrate this technical solution.

[0073] S1: guinea pig

[0074] SPF grade guinea pigs with a body weight of 300-500g were raised in IVC cages (3 guinea pigs per cage, the litter was changed twice a week, free access to food and water).

[0075] S2: skin test

[0076] Tuberculin pure protein derivative skin test negative guinea pigs.

[0077] S3: Allergens

[0078] Allergens (50 mg / mL) of Mycobacterium kansasii (CMCC 95013), Mycobacterium marinum (CMCC 95014) and Mycobacterium simianus (CMCC95015) were taken and sterilized at 121°C for 20 minutes.

[0079] S4: Sensitization

[0080] Inject 0.2mL of the allergenic bact...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a product based on an intracellular mycobacterium pure protein derivative and a recombinant mycobacterium tuberculosis fusion protein and application of the product, and belongs to the technical field of biological protein. According to the present invention, the tuberculosis and the NTM disease can be rapidly identified (within 24 h) through the combined use of the intracellular mycobacterium pure protein derivative and the recombinant mycobacterium tuberculosis fusion protein (EEC), and the tuberculosis is determined when the delayed hypersensitivity reactions of the intracellular mycobacterium pure protein derivative and the recombinant mycobacterium tuberculosis fusion protein (EEC) are completely positive; and when the delayed hypersensitivity reaction of the intracellular mycobacterium pure protein derivative is positive and the delayed hypersensitivity reaction of the recombinant mycobacterium tuberculosis fusion protein (EEC) is negative, the disease is NTM disease. The invention aims to provide a product based on an intracellular mycobacterium pure protein derivative and a recombinant mycobacterium tuberculosis fusion protein and application of the product, so that tuberculosis and NTM diseases are quickly identified, and a reliable basis is provided for an accurate treatment scheme of a patient.

Description

technical field [0001] The invention relates to a protein product and its application, in particular to a product, application and use method based on a pure protein derivative of Mycobacterium intracellulare and a recombinant Mycobacterium tuberculosis fusion protein, and belongs to the technical field of biological proteins. Background technique [0002] Tuberculosis is a chronic infectious disease that seriously endangers human and animal health. In 2019, there were 1.4 million deaths from tuberculosis worldwide. According to the 2020 global tuberculosis annual report released by the WTO: the number of global tuberculosis cases in 2019 is estimated to be about 10 million (8.9-11 million); among them, India is 2.64 million, accounting for 26%; Indonesia is 846,000, accounting for 8.5%; China is 833,000, accounting for 8.5%. 8.4%. The number of tuberculosis patients in China ranks third in the world, and it is a country with a high burden of tuberculosis. [0003] For non...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K49/00C07K19/00
CPCA61K49/0006C07K14/35C07K2319/00
Inventor 孙超伟
Owner 成都可恩生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com